Oramed Pharmaceuticals Inc (ORMP)
2.37
+0.02
(+0.85%)
USD |
NASDAQ |
Apr 24, 16:00
2.375
0.00 (0.00%)
After-Hours: 20:00
Oramed Pharmaceuticals Enterprise Value: -15.93M for April 24, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
April 24, 2024 | -15.93M |
April 23, 2024 | -16.74M |
April 22, 2024 | -17.55M |
April 19, 2024 | -19.98M |
April 18, 2024 | -22.82M |
April 17, 2024 | -17.55M |
April 16, 2024 | -14.72M |
April 15, 2024 | -13.91M |
April 12, 2024 | -9.854M |
April 11, 2024 | -7.422M |
April 10, 2024 | -4.181M |
April 09, 2024 | -2.965M |
April 08, 2024 | 0.2762M |
April 05, 2024 | -6.207M |
April 04, 2024 | -6.207M |
April 03, 2024 | -0.5342M |
April 02, 2024 | 1.492M |
April 01, 2024 | 2.707M |
March 28, 2024 | 6.354M |
March 27, 2024 | 2.302M |
March 26, 2024 | -1.750M |
March 25, 2024 | -0.129M |
March 22, 2024 | 5.949M |
March 21, 2024 | 1.492M |
March 20, 2024 | 7.975M |
Date | Value |
---|---|
March 19, 2024 | 2.707M |
March 18, 2024 | 1.897M |
March 15, 2024 | 6.354M |
March 14, 2024 | -3.370M |
March 13, 2024 | 0.2762M |
March 12, 2024 | 3.923M |
March 11, 2024 | 7.164M |
March 08, 2024 | 8.785M |
March 07, 2024 | 3.923M |
March 06, 2024 | 4.328M |
March 05, 2024 | 19.54M |
March 04, 2024 | 19.14M |
March 01, 2024 | 26.00M |
February 29, 2024 | 20.75M |
February 28, 2024 | 25.59M |
February 27, 2024 | 32.45M |
February 26, 2024 | 31.24M |
February 23, 2024 | 27.61M |
February 22, 2024 | 21.16M |
February 21, 2024 | 17.53M |
February 20, 2024 | 15.11M |
February 16, 2024 | 14.70M |
February 15, 2024 | 14.70M |
February 14, 2024 | 14.30M |
February 13, 2024 | 10.27M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-80.02M
Minimum
Jan 26 2023
1.038B
Maximum
Nov 08 2021
121.94M
Average
44.83M
Median
Enterprise Value Benchmarks
Inogen Inc | 35.98M |
Petros Pharmaceuticals Inc | -0.5521M |
DIH Holding US Inc | -- |
NovaBay Pharmaceuticals Inc | 2.284M |
Palatin Technologies Inc | 18.43M |
Enterprise Value Related Metrics
Net Income (Quarterly) | 13.34M |
Total Expenses (Quarterly) | 3.877M |
EPS Diluted (Quarterly) | 0.33 |
Earnings Yield | 5.91% |
Normalized Earnings Yield | -21.52 |